Country: Sweden
Language: Swedish
Source: Läkemedelsverket (Medical Products Agency)
cinnarizin; dimenhydrinat
Medochemie Ltd
N07CA52
cinnarizine; dimenhydrinate
20 mg/40 mg
Tablett
dimenhydrinat 40 mg Aktiv substans; cinnarizin 20 mg Aktiv substans
Receptbelagt
Förpacknings: Blister, 20 tabletter; Blister, 30 tabletter; Blister, 50 tabletter; Blister, 100 tabletter
Godkänd
2019-11-05
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT AZALONUM 20 MG/40 MG TABLETS cinnarizine/dimenhydrinate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Azalonum is and what it is used for 2. What you need to know before you take Azalonum 3. How to take Azalonum 4. Possible side effects 5. How to store Azalonum 6. Contents of the pack and other information 1. WHAT AZALONUM IS AND WHAT IT IS USED FOR Azalonum contains two active ingredients. One is cinnarizine and one is dimenhydrinate. The two substances belong to different groups of medicines. Cinnarizine is part of a group called calcium antagonists. Dimenhydrinate belongs to a group called antihistamines. Both substances work by reducing symptoms of vertigo (a feeling of dizziness or ’spinning’) and nausea (feeling sick). When these two substances are used together they are more effective than when each one is used on its own. Azalonum is used for the treatment of various kinds of vertigo in adults. Vertigo can have a number of different causes. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE AZALONUM DO NOT TAKE AZALONUM: if you are allergic to cinnarizine, dimenhydrinate or diphenhydramine or any of the other ingredients of this medicine (listed in section 6). if you are allergic to any other antihistamines (such as astemizole, chlorpheniramine and terfenadine, used as allergy medicines). You should not take this medicine unless you have been told to by your doctor. if you suffer from angle-closure glaucoma (a specific type of eye dise Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Azalonum 20 mg/40 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg cinnarizine and 40 mg dimenhydrinate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. White to off white, round, biconvex tablets with diameter 8 mm 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of vertigo symptoms of various origins. Azalonum is indicated in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults_ 1 tablet three times daily. In general, the duration of treatment should not exceed four weeks. The physician shall decide whether longer treatment is required. _Elderly_ Dosage as for adults. _Renal impairment_ Azalonum should be used with caution in patients with mild to moderate renal impairment; Azalonum should not be used by patients with a creatinine clearance of ≤ 25 mL/min (severe renal impairment). _Hepatic impairment_ No studies in patients with hepatic impairment are available. Azalonum should not be used by patients with severe hepatic impairment. _Paediatric population_ The safety and efficacy of Azalonum in children and adolescents under the age of 18 years has not been established. No data are available. Method of administration Oral administration. Azalonum tablets are to be swallowed with some liquid after meals. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substances, diphenhydramine or other antihistamines of similar structure or to any of the excipients listed in section 6.1. Diphenhydramine is completely excreted renally, and patients with severe renal impairment were excluded from the clinical development programme. Azalonum should not be used by patients with a creatinine clearance of ≤ 25 ml/min (severe renal impairment). Since both active components of Azalonum are extensively metabolised by hepatic cytochrome P450 enzymes, the plasma concentrations of the unchanged drugs and their half-lives will increase in patients with Read the complete document